Marizomib, A Potent Second Generation Proteasome Inhibitor from Natural Origin

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 3, 2015-03 ,pp. : 298-306

Bentham Science Publishers

Access to resources Recommend Favorite

A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 10, 2015-12 ,pp. : 1297-1304

Bentham Science Publishers

Access to resources Recommend Favorite

MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma

By Amato Robert J.   Stephenson Joe   Hotte Sebastien   Nemunaitis John   Bélanger Karl   Reid Gregory   Martell Robert E.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 415-421

Informa Healthcare

Access to resources Recommend Favorite

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer

By Zielinski Robert   Chi Kim N  

Future Oncology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1239-1251

Future Medicine

Access to resources Recommend Favorite

Second-generation interferons for cancer: clinical targets

By Borden E.C.   Lindner D.   Dreicer R.   Hussein M.   Peereboom D.  

Seminars in Cancer Biology, Vol. 10, Iss. 2, 2000-04 ,pp. : 125-144

Academic Press

Access to resources Recommend Favorite